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Human lymphocyte subpopulations were originally classiﬁed as T- and B-cells in the 70s. Later, with the development of
monoclonal antibodies, it became possible to recognize, within the T-cells, functional populations: CD4
+ and CD8
+.T h e s e
populations were usually referred to as “helper” and “suppressor” cells, respectively. However several investigations within the
CD8 cells failed to detect a true suppressor activity. Therefore the term suppressor was neglected because it generated confusion.
Muchlater,truesuppressoractivitywasrecognizedinasubpopulationofCD4cellscharacterizedbyhighlevelsofCD25.Thenovel
population is usually referred to as T regulatory cells (Tregs) and it is characterized by the expression of FoxP3. The heterogeneity
of CD4 cells was further expanded by the recent description of a novel subpopulation characterized by production of IL-17. These
cells are generally referred to as TH17. They contribute to regulate the overall immune response together with other cytokine-
producing populations. Treg and TH17 cells are related because they could derive from a common progenitor, depending on the
presence of certain cytokines. The purpose of this review is to summarize recent ﬁndings of the role of these novel populations in
the ﬁeld of human gastroenterological disease.
Copyright © 2009 Franco Pandolﬁ et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
In 1970 Gershon and Kondo described the role of T-
lymphocytes in the induction of tolerance [1]. Much later
true regulatory activity was recognized in a subpopulation of
CD4+ cells characterized by high levels of CD25, the alpha-
chain of IL-2 receptor [2]. This novel population is usually
referred to as T regulatory cells (Tregs). IL-2 is essential for
the generation of Tregs in the thymus and their survival,
expansion, and suppressive function in the periphery [3].
The presence of alternative patterns of cytokine pro-
duction has been well established in several pathological
conditionsandisusuallyreferredtoasTH1cellsthatproduce
IL-2andINF-gammabutnotIL-4andTH2cellsthatproduce
IL-4 but not IL-2/IFN-gamma. Yet, the concept that the cells
producing these alternative patterns of cytokines represent
in humans irreversibly diﬀerentiated endpoints has been
challenged [4, 5]. However, for the sake of simplicity, we
w i l l ,a si ti su s u a l l yd o n e ,r e f e rt ot h e s ec e l l sa sT H1a n dT H2
indicating not diﬀerentiated population but their pattern of
cytokine production.
In this review we discuss experimental evidences derived
from both human and mouse studies. For the sake of clarity,
the reader should assume that we are reviewing human data
unless diﬀerently speciﬁed.
2. Regulatory T-Cells (Tregs)
Regulatory T-cells constitute a minor subpopulation of
CD4+ T-cell but their role is crucial for the control of
autoreactive T-cells [6]. Naturally occurring CD4+CD25+
T-cells represent 5%–10% of peripheral CD4+ cells [7, 8].
They develop in the thymus from nonregulatory thymocytes
during ontogeny [9]. Nevertheless not all the CD4+CD25+
T-cells can be considered Tregs. Most of the regulatory
T-cells are CD4+CD25high cells, which represent 2%-3%
of the CD4+ T-cells [10]. However, recent data supports2 Mediators of Inﬂammation
the idea that Tregs can also be CD25 negative [11, 12].
Regulatory T-cells are involved in the regulation of immune
response, maintaining immunological self-tolerance and
immune homeostasis [13], and the control of autoimmunity
and cancer surveillance [14]. Therefore, Tregs play a key role
in autoimmunity, allergy, cancer, infectious disease, and the
induction of transplantation tolerance. As a consequence,
abnormalities in the number and functions of Tregs have
been implicated in the pathogenesis of the abovementioned
clinical conditions [15].
Tregs are characterized by the expression of FoxP3
(Forkhead box P3), a transcriptional repression factor of
the forkhead-winged helix family of transcription factors
[16]. FoxP3 is physically associated with the Rel family
transcription factors, nuclear factor of activated T-cells
(NFATs) and NF-kappaB (NF-κB), and blocks their ability
to induce the endogenous expression of their target genes,
including key cytokine genes [17]. Mutations in FoxP3 are
associated with the inherited autoimmune disease, Scurfy in
mice, and IPEX (immune dysregulation, polyendocrinopa-
thy, enteropathy, and X-linked syndrome) in human [18].
IPEX is characterized by the presence of autoimmune disease
in multiple endocrines organs, inﬂammatory bowel disease,
allergies,andsevereinfections[16].BeyondIPEX,mutations
of FoxP3 have been seen associated also with an absence of
Tregs [19].
A further evidence of the importance of FoxP3 derives
from the observation by Hori et al. that retroviral gene
transfer of FoxP3 converts naive T-cells into a regulatory T
cell phenotype similar to that of naturally occurring CD4+
regulatory T-cells [20]. FoxP3 can also interact with the
promoterofIL-127receptor(IL-127R)andmightcontribute
toreduceexpressionofCD127inTregs.Thus,CD127expres-
sion inversely correlates with FoxP3 expression [21]. In 2008
Sakaguchi proposed FoxP3 as the crucial marker for Tregs
development and function [14], and FoxP3 is currently one
of the most accepted markers for Tregs. So Tregs are usually
referred to phenotypically as CD3/CD4/CD25high/FoxP3+
cells. Recently, after the description of an inverse relationship
between the expression of FoxP3 and CD127 [21], it has
become possible to deﬁne an alternative phenotype of Tregs
as CD3/CD4/CD25high/CD127− cells.
In summary, FoxP3, IL-2, and CD25 are essential
molecules for the development, function, and survival of
Tregs.ItisworthnotingthatinductionofFoxP3isalsounder
the control of TCR and CD28 signaling. Moreover IL-2 and
TGF-beta are important for the survival and proliferation of
Treg cell precursors [22, 23].
A subset of human Tregs the FoxP3+ regulatory
eﬀector/memory-like T- (TREM) cells expresses CD39, nucle-
oside triphosphate diphosphohydrolase-1 [NTPDase 1], an
ectoenzyme that degrades ATP to AMP. Diﬀerent from
mice, in which CD39 is expressed in all Tregs, in humans
CD39 is a marker of a Treg subset likely involved in the
control of the inﬂammatory autoimmune disease [24]. So,
the expression of CD39 in concert with CD73, another
ectonucleotidase present on the surface of lymphocytes, can
further distinguish CD4+/CD25+/FoxP3+ Treg cells from
other T-cells [25].
Alpha(E)beta(7)-integrin (CD103) is an integrin that
enable the interaction with epithelial cadherin responsible
for tissue-speciﬁc retention of lymphocytes. Thus, the inte-
grin alpha(E)beta(7) can be regarded as a novel marker for
subsets of functionally distinct Tregs specialized for crosstalk
with epithelial environments [26]. CD103 has been seen also
connected to the retention and homing of Tregs in inﬂamed
tissues [27].
3. Tregs Subpopulations
Tregs are divided into two subpopulations, which are
primarily deﬁned by where they develop:
(1) the natural Tregs (nTregs), which originate directly
from the thymus, expressing at once high levels of
CD25 and the transcriptional factor FoxP3,
(2) the induced Tregs (iTregs), develop in the periphery
from conventional CD4+ T-cells and whose expres-
sion can be modulated through antigenic stimulation
under a variety of conditions.
A functionally important proportion of Tregs (the
nTregs) originates from the thymus; nevertheless, in 2006,
Chatenoud and Bach reported that Tregs are not present as
such in the thymus; they derive from peripheral precursors
that are CD4+CD25− and diﬀerentiate into functional Tregs
followingadequatestimulationinthepresenceofthecognate
antigen and specialized immunoregulatory cytokines, such
as TGF-beta, IL-10, and IL-4; they are generally termed
“adaptive” Tregs [28].
In addition several pathological and tolerogenic condi-
tions, suchasoral toleranceandthepresenceof retinoic acid,
induce conversion of conventional T-cells into Treg cells. In
particular, it has been shown that, in the presence of TGF-
beta, all-trans-retinoic acid (ATRA) eﬃciently converts adult
human peripheral blood naive CD4+ T-cells into Treg cells
with stable and potent suppressive ability [29].
Moreover it has been demonstrated that a substantial
percentage of Tregs had transient or unstable expression of
the transcription factor FoxP3. These cells have been deﬁned
as “exFoxP3” T-cells, and they have an activated-memory
T-cell phenotype and produce inﬂammatory cytokines.
exFoxP3cellnumbersincreaseininﬂamedtissuesinautoim-
mune conditions. Analysis of the T-cell receptor repertoire
suggested that exFoxP3 cells developed from both natural
and adaptive Tregs [30].
4. Mechanisms of Action of Tregs
Several mechanisms have been proposed to explain the
function of Tregs, but the eﬀective mechanism of action of
Tregs is not yet completely understood. Despite the numer-
ous studies performed about Tregs functions, a number of
fundamental questions concerning the origin, phenotypic
nature, and mechanism of action of Tregs remain still elusive
[15].
Currently it is believed that Tregs rely on several mecha-
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(1) The ﬁrst mechanism is metabolic disruption.
(2) Tregs may regulate their target by modulating DC
maturation via CD80/86 and CTLA-4 interactions.
(3) Another mechanism is the cytolysis mediated by
granzyme A or B in human and mice, respectively.
(4) Moreover Tregs can produce inhibitory cytokines,
such as IL-10, TGB-beta, and IL-35.
(5) Finally Tregs are involved also in the regulation of
peripheral tolerance to self-antigens.
Tregs were described initially as antigen nonspeciﬁc
cells that act through an APC (Antigen Presenting Cell)
independent mechanism. Tregs require activation via their
TCR to become suppressive; but once activated, their
suppressor eﬀector function is completely nonspeciﬁc [31].
Nevertheless, subsequently it has been veriﬁed that may exist
populations of Tregs that are antigen speciﬁc. More recently,
a much larger analysis of hundreds of TCRs found little
evidence that the Tregs population preferably recognized
self-antigen; besides it was concluded that non-self-antigens
are the cognate speciﬁcities of Tregs [32].
Other studies concluded that Tregs, like conventional T-
cells, have a polyclonal TCR repertoire and are selected on
self-peptides.Speciﬁcityforself-peptidesdirectstheselection
of CD4+CD25+ regulatory thymocytes by a process that is
distinct from positive selection and deletion [33].
The growing number of inhibitory mechanisms ascribed
to Tregs suggests that these cells take a multipronged
approach to immune regulation. It is likely that the relative
importance of each inhibitory mechanism is context depen-
dent and modulated by the inﬂammatory milieu and the
magnitude of the immune response. Taken together, these
mechanisms provide a potent arsenal with which Tregs can
act [34, 35].
4.1. Metabolic Disruption. Because of the presence of the
alpha chain of IL-2 receptor (CD25), Tregs could be scav-
engers of IL-2, inhibiting the activation of other T-cells in
the same environment, reducing the IL-2 availability. They
do not produce IL-2, thus depend on IL-2 production by
other cells. Reducing IL-2, Tregs induce apoptosis by IL-
2 deprivation, which has been shown in several clinical
conditions, including HIV disease [36].
Besides, these cells express also the transcriptional
repression factor FoxP3 which is involved in the inhibition
of cellular activity. So Tregs could consume IL-2 without
activating their immune function and preventing, at the
same time, the activation of other T-cells.
Moreover, because of the presence of the ectoenzymes
CD39 and CD73 on the cellular surface of Tregs, these
cells are also able to modulate cellular inhibition, through
the production of pericellular adenosine (Ado) from ATP.
ATP and Ado are important endogenous signaling molecules
in immunity and inﬂammation. Extracellular ATP is a
danger signal released by damaged cells; ATP behaves as
chemoattractant for lymphocytes, activator of proinﬂamma-
tory response, and inducer of local pain [37].
4.2. Cell-to-Cell Inhibition. One additional possibility to
explain Tregs function is based on observation by Vignali
[38], who referred that Tregs can mediate their inhibitory
function by direct cell-to-cell contact. Wing et al. described
the role of cytotoxic T-lymphocyte antigen-4 (CTLA-4), a
proteinhighlyexpressedbyTregs,whichinhibitstheimmune
response [39]; CTLA-4 binds the costimulatory molecules
CD80 (B7-1) and CD86 (B7-2) with higher aﬃnity than
CD28, inhibiting the second signal, necessary to immune
activation [40]. Constitutive expression of CTLA-4 among
CD4+ cells was restricted primarily to Tregs, suggesting
that CTLA-4 expression by these cells is involved in their
immune-suppressive function. These ﬁndings raise the pos-
sibility that Treg cell function contributes to the immune
suppression characteristic of CTLA-4 signaling [41]. In vivo
blockade of CTLA-4 for a limited period in normal mice
leads to spontaneous development of chronic organ-speciﬁc
autoimmunediseases,whichareimmunopathologicallysim-
ilar to human counterparts [42]. CTLA-4 is constitutively
expressed on Tregs that express the transcriptional factor
FoxP3. Furthermore, ectopic FoxP3 expression can pheno-
typically convert eﬀector T-cells to regulatory T-cells [43].
Horwitz et al. revealed an important relationship between
TGF-beta,CTLA-4,andFoxP3inthegenerationofiTreg,but
not nTreg [44].
Tregs also express the glucocorticoid-induced tumor
necrosis factor receptor family-related gene (GITR, also
known as TNFRSF18), a member of the tumor necro-
sis factor-nerve growth factor (TNF-NGF) receptor gene
superfamily, which plays a key role in dominant immuno-
logical self-tolerance [45]. Stimulation of GITR abrogate
CD4+CD25+ T-cell-mediated suppression and administra-
tion of a monoclonal antibody to GITR produce organ-
speciﬁc autoimmune disease in otherwise normal mice [46].
One other cell surface molecule, Lymphocyte activation
gene-3 (LAG-3), marks regulatory T-cell populations and
contributes to their suppressor activity [47]. LAG-3 is a
CD4-relatedtransmembraneproteinexpressedbyregulatory
T-cells that binds MHC II on APCs. During Tregs-DCs
interactions, LAG-3 engagement with MHC class II inhibits
DC activation [48].
Another possibility of inhibition cell-to-cell contact-
mediated of Tregs is based on the interactions, in lym-
phoid tissues, between Tregs and dendritic cells (DCs).
In fact activated professional APCs (DCs, B-cells, and
macrophages) can attract Tregs, through the secretion of
common chemokines, such as CCL4, which is the most
potent chemoattractan of Tregs [49]. Then, the cellular
relation with DCs and Tregs helps to restrict DCs ability to
form stable contacts with self-reactive T-cells, resulting in
only transient interactions between DCs and na¨ ıve CD4+ T-
cells [50].
4.3. Cytotoxic Activity. T r e g sc a ns u p p r e s si m m u n er e s p o n s e
also inducing apoptosis; this requires, in the target T-cells,
the proapoptotic protein Bim, involved in the activation of
caspases cascade [51]. Apoptotic mechanisms are used to
regulatethedevelopmentofthymocytes,theshapingofTcell
repertoire, its selection, and the coordinate events leading to4 Mediators of Inﬂammation
immune responses in the periphery [52]. Tregs can also con-
trol the immune response mediating the perforin/granzyme
pathway; in fact Grossman et al. have shown that human
adaptive Treg cells preferentially express granzyme B and can
kill allogeneic target cells in a perforin-dependent manner.
In humans, when Tregs are activated, they express granzyme
A, but very little granzyme B [53]. This evidence shows
that Tregs objectify their regulatory activity also through
suppression by cytotoxic activity.
Granzyme B is also important for the ability of NK cells
and CD8+ T-cells to kill their targets. Recent data in the
mouse has reported the important role of granzyme B in
the suppression of immune system against tumor. In fact
granzyme B has not been shown to be expressed in naive
Treg cells but it is highly expressed in 5%–30% of Tregs in
the tumor environment. Thus, in mouse, both granzyme B
and perforin are relevant for Treg cell-mediated suppression
of tumor clearance in vivo [54].
4.4. Inhibitory Soluble Factors. In contrast to these hypothe-
ses of cell-contact suppression, there are quite a few reports
indicating that Tregs could secrete several cytokines, as
TGF-beta and IL-10, for mediating suppression reviewed
in [55], limiting eﬀector T-cells function, and inhibiting
recruitment of inﬂammatory myeloid cells such as neu-
trophils, eosinophils, and monocytes [50]. For instance, IL-
10 is required for the control of colitis and homeostatic
maintenance of the T-cell number by Tregs review in [55].
However, the production of IL-10 and TGF-beta by Tregs has
been challenged by others [56].
IL-35, an inhibitory cytokine of recent description, may
bespeciﬁcallypr oduc edb yT r egsandisr equir edformaximal
suppressive activity [57].
4.5. Peripheral Tolerance. Moreover Tregs are also involved
in the induction of peripheral tolerance to self-antigen.
Tolerance to self-antigens is generated through two funda-
mental mechanisms, which included the elimination of self-
reactive cells in the thymus during selection (central toler-
ance) and generation of a variety of peripheral regulatory
cells to control self-reactive cells that escape the thymus
(peripheraltolerance)[43].So,attheperipheralmechanisms
of tolerance in CD4+ T-cells, which included functional
anergy and deletion [58], it is also possible to include the
functionofsuppressionbyTregs.Thus,theexistenceofTregs
that actively suppress the function of conventional T-cells
is a key mechanism by which the immune system limits
inappropriate or excessive response [15].
5. TH17 Cells
The heterogeneity of CD4 T-cells was further expanded by
the recent description of the novel subpopulation TH17,
characterized by potent proinﬂammatory properties. These
cells, together with T-cells populations, which mainly pro-
duceaTH1orT H2patternofcytokines,INF-gamma,andIL-
4, respectively, regulate the overall immune response. Since
their discovery, eﬀorts have been made in characterizing
human TH17 cells and the factors involved in their diﬀer-
entiation and in understanding the role that these cells play
in inﬂammation, protective immunity, and autoimmune
diseases [59].
CD4+ T-helper (TH17) cells are characterized by the
production of IL-17A and IL-17F [60]. TH17 cells have
recently been deﬁned as a unique subset of proinﬂammatory
helper T-cells whose development depends on signaling
initiated by IL-6 and TGF-beta, autocrine activity of IL-
21, activation of STAT3, and induction of the retinoic acid
related orphan nuclear receptor RORgammat [61].
T-helper cells produced from the thymus develop into
diﬀerent diﬀerentiation program, controlled by cytokines
produced in response to microbial products by innate
immune cells. Each diﬀerentiation program, other than
being characterized by unique cytokine proﬁle, INF-gamma
for TH1c e l l sa n dI L - 4f o rT H2, can also be identiﬁed by
speciﬁctranscriptionfactor,aspivotalregulatoroftheT-cells
diﬀerentiation. These transcription factors include T-bet for
TH1c e l l s ,a n dG A T A - 3f o rT H2 cells [62].
RORgammat does not function in isolation but coordi-
nates the activity of a series of other essential transcription
factor in guiding the diﬀerentiation of TH17 cells [62].
RORgammatinducestranscriptionofthegenesencodingIL-
17 and the related cytokine IL-17F in naive CD4+ T-helper
cells and is required for their expression in response to IL-6
and TGF-beta, the cytokines known to induce IL-17. TGF-
beta together with IL-6 or IL-21 initiates the diﬀerentiation,
while the IL-23 stabilizes the generation of TH17 cells [63].
Moreover, TH17cellsarealsocharacterizedbythesurface
expression of CCR6, IL-23R, IL-12Rbeta2, and CD161. They
also can express the transcription factor T-bet in addition to
RORgammat.
The origin of TH17 cells is controversial: in human, TH17
cells originate from CD161+ naive CD4+ T-cells precursor,
which constitutively express RORgammat and IL-23R, in
response to the combined activity of IL-1beta and IL-23.
These ﬁndings implicate CD161 as a novel surface marker
for human TH17 cells and demonstrate the exclusive origin
of these cells from a CD4+ CD161+ T-cell progenitor [64].
TH17 cells play a role in various human diseases associ-
ated with inﬂammation and destruction such as rheumatoid
arthritis, psoriasis, Crohn’s disease, and multiple sclerosis,
where IL-17 can be seen as a therapeutic target. These
diseases have in common the local chronic inﬂammatory
reaction with production of inﬂammatory cytokines, leading
to matrix destruction and defective repair [65]. Infectious
disease mouse models indicate that TH17 cells mediate
protection against extracellular pathogens [66]. TH17 may
also contribute to tumor progression due to the role of their
cytokines in inﬂammation and tissue repair [67].
6. Plasticityof CD4+ T-cells: Connectionwith
Tregs and TH17 Cells
The diﬀerentiation of T-cells into several diﬀerentiation
lineages with distinct eﬀector function is well established
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CD4+ T-cell populations, such as TH1a n dT H2 cells, nTregs
and iTregs, and TH17 cells, it is not more possible to
enunciate with absolute certainty that these CD4+ T-cells
subsets represent irreversibly diﬀerentiated endpoints [5].
The development into TH1 7c e l l sh a sn o tb e e nc o n s i d e r e dt o
represent a terminal product of its developmental program
[68]. Moreover, it appears that expression of FoxP3 by iTregs
or IL-17 by TH17 cells may not be stable and that there is
a great degree of ﬂexibility in their diﬀerentiation options
[5].
There is a close relation between Tregs and TH17 cells.
Whileinmicethesecellsoriginatefromacommonprecursor,
in human it has been reported a developmental link between
Tregs and TH17 cells, in which TGF-beta is essential for
the generation of both cells [63]. TGF-beta orchestrates
TH17 and Tregs diﬀerentiation in a concentration-depended
manner [62]. At low concentration, TGF-beta synergizes
with IL-6 and IL-21 to promote IL-23R expression, favoring
TH17 cell diﬀerentiation. High concentration of TGF-beta
represses IL-23R expression and favors FoxP3+ Treg cells
[69]. Besides, there is also an inverse correlation with the
transcription factors that identify each of these two T-cell
subpopulations.InfactinthepresenceofTGF-beta,CD4+ T-
cells express both RORgammat and FoxP3, but RORgammat
function is antagonized by FoxP3. Rather in the presence
of proinﬂammatory cytokines and low concentration of
TGF-beta, RORgammat expression is further upregulated,
whereas FoxP3 expression and function are inhibited. These
evidences show the importance of cytokines environment
in the diﬀerentiation of CD4+ T-cell subsets, depending
upon the balance of expression of the transcriptional factors
RORgammat and FoxP3.
Moreover, several recent publications have demonstrated
the importance of retinoic acid in the plasticity between
Tregs and TH17 cells. Retinoic acid has been demonstrated
to be a key regulator of TGF-beta dependent immune
responses, capable of inhibiting the IL-6-driven induc-
tion of proinﬂammatory TH17 cells and promoting anti-
inﬂammatory Treg cell diﬀerentiation [70].
7.Tregs andTH17 Cells in
GastrointestinalTumors
Tregs play also a crucial role in the modulation of the
immune response to tumor. In particular Tregs are inversely
correlated with prognosis of human neoplasias. An increase
of their number is associated to a more high risk of incidence
of tumors. Compared with healthy patients, patients with
gastrointestinal malignancies had a higher proportion of
CD4+ CD25+ T-cells in peripheral blood [71].
Most available studies are related to the number of Tregs
in peripheral blood of patients with solid tumors. However
the most critical point could be to evaluate the presence of
Tregs at the site of tumor. It has been shown that many solid
tumors are characterized by the inﬁltration of lymphocytes,
and this presence of Tissue inﬁltrating lymphocytes (TILs).
It is essential to determine the T-cell subsets involved in
the immune response to understand the pathogenesis of
immune diseases [72, 73].
Tregs have been associated with prevention of antitumor
immunity and the evasion of eﬃcient recognition of tumor
antigens. TILs have been shown to possess a speciﬁcity
to tumor-associated antigens (TAAs), which are often self-
antigens. Analysis of the composition of the speciﬁc T-cell
receptor (TCR) of TIL could thus provide information on
the nature of the antigens recognized by TIL [74].
Many studies have revealed that Tregs are increased in
several malignancies, such as esophageal cancer [75], gastric
cancer [76], pancreatic cancer [77], and hepatocellular
cancer (HCC) [78]. The increasing proportion of Tregs may
be related to immunosuppression and tumor progression
in patients with gastrointestinal malignancies. There are
several evidences concerning the inverse correlation with the
prevalence of Tregs and the prognosis of tumors. While it
has been reported a direct connection with the increase of
these cells and a poor prognosis in esophageal and gastric
cancer, in pancreatic cancer and in HCC, there has already
not been reported a signiﬁcant diﬀerence by clinical stage
in the prevalence of Tregs among patients with colorectal
carcinoma [71].
Because of their recent discovery, the role of TH17 cells
in tumor is poorly understood. TH17 cells increase in gastric
cancer [79], colorectal cancer, and HCC [80].
T h er o l eo fT H17 cells has emerged as instrumental in
cancer pathogenesis, since IL-17 promotes tumor growth,
whether IL-23, also produced by TH17, is considered a
cancer-associated cytokine because it promotes tumor inci-
dence and growth.
In addition, TH17 cells have recently been described to
contribute to human tumor immunity by inducing TH1
cytokines and recruit eﬀector cells to the tumor environment
[81].
8. Esophageal and GastricCancers
The direct relationship between the prevalence of Tregs in
PBMCs and in TILs and the clinical outcome in patients
with esophageal and gastric cancers is shown through several
clinical evidences. In fact patients with these cancers have
higher proportions of Tregs compared with healthy patients.
The population of Tregs in patient with advanced esophageal
and gastric cancers was signiﬁcantly larger than that in
patients with early esophageal and gastric cancers, both in
PBMCs and TILs [75, 82]. In addition patients with these
tumors,whohavehigherlevelsofTregs,showmoreadvanced
stages and poorer survival rates.
9.PancreaticAdenocarcinoma
In pancreatic cancer high levels of Tregs have been found
as a marker of bad prognosis. The prevalence on Tregs is
signiﬁcantly higher in the peripheral blood, in the tumor
microenvironment, and even in the lymph nodes TILs in
the lymphatic metastasis, compared with normal donors
[83]. Recent publication describes the expression of FoxP3 in
pancreatic ductal adenocarcinoma cells, providing evidence
that this could be an important tumor escape mechanism
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10.HepatocellularCarcinoma(HCC)
It has been demonstrated that lymphocytic inﬁltration of the
cancerous tissue of liver is indicative of a better survival after
surgical resection of the tumor [85]. This evidence conﬁrms
the importance of the TILs in the favorable outcome of
tumor. However patients with HCC have increased number
of Tregs in their peripheral blood and there are also
comparable high numbers of Tregs in TILs of the tumor
microenvironment. This datum suggests that the increase
in frequency of Tregs may play a role in modulation of the
immune response against HCC and could be important in
design of immunotherapeutic approaches [78].
11. Tregs in Liver Transplant
The liver is a privileged organ with a lower incidence of
rejection than other organs. Recent evidence has pointed
out that some transplanted patients can achieve operational
tolerance, allowing withdrawal of immunosupression. This
event is associated with increased levels of Tregs [86]. Tregs
have been shown to play a pivotal role in transplant tolerance
[87]; regarding their function of suppressive cells, Tregs may
play a role in the regulation of alloreactivity.
12.Inﬂammatory BowelDisease asResult
of Imbalance of Proinﬂammatoryand
Regulatory T-Cells Responses
Inﬂammatory bowel diseases (IBDs), comprising Crohn’s
Disease (CD) and Ulcerative Colitis (UC), are characterized
bychronicidiopathicintestinalinﬂammation,resultingfrom
predisposing genetic (genes encoding proteins relevant to
both innate and adaptive immunity: NOD2, STAT3, and IL-
23 receptor, etc.) and environmental factors (speciﬁc Toll-
like receptors (TLRs) ligands and antigens derived from
commensal bacteria) acting on immunoregulatory system.
IBD may be result of an imbalance of proinﬂammatory and
regulatory T-cells responses.
Studies of Tregs in celiac disease are anecdotal. A recent
work shows a higher percentage of circulating Tregs in
patients with active disease than patients after dietary treat-
ment; this experimental evidence suggests that Tregs could
act in extinguishing the ongoing intestinal inﬂammation and
the immune response to dietary gluten antigens [88]. In IBD,
the inﬂammation is induced by many diﬀerent cytokine-
mediated pathways [89]. IL-23, IL-17, and the recently
described IL-32 [90] have been linked to the pathogenesis of
several inﬂammatory disorders, including IBD.
Data available before the full characterization of TH17
cells implicated a TH1 cytokine proﬁle in the pathogenesis of
Crohn’s disease. More recently, mouse models revealed that
tissue inﬂammation does not develop in mice deﬁcient in
the IL-23p19 subunit, whereas inﬂammation can be found
in IL-12p35 deﬁcient mice, suggesting that these models are
associated with TH17 responses [91].
Studies in humans are anecdotal, but, latterly an
increased number of RORgammat expressing cells have been
detected in the lamina propria of patients with Crohn’s
disease [92]. In addition, TH17 cells were isolated from
inﬂamed lesions of Crohn’s patients [93]. Subsequently,
increasing interest in the pathogenesis of IBD has been
attracted by the role of retinoic acid.
A sB a ie ta l .p u ti t[ 94], vitamin A and its metabolites,
such as retinoic acid (RA), are active agents with a broad
range of functions involving immune cell diﬀerentiation
andmaintainingimmunehomeostasis.Forinstance,vitamin
A and its metabolites are capable of ameliorating various
models of autoimmunity.
Deﬁciency of vitamin A can lead to exacerbated experi-
mental colitis, and supplementation of vitamin A results in
amelioration of diarrhea.
Elias et al. have shown that all-transretinoic acid (ATRA)
and other agonists of the retinoic acid receptor alpha
(RARalpha) inhibit the formation of TH17 cells and promote
FoxP3 expression [95], while Benson et al. have reported that
ATRA enhances Treg growth and diﬀerentiation [96].
The close link between IL-23 and IL-17 has been
reported as IL-23/IL-17 axis. If an important role of IL-
23 is emerging, the function of IL-17 in IBD remains still
unclear. According to what was reviewed by O’Connor et
al. [97], it has been veriﬁed that the absence of IL-17A or
IL-17R in T-cells led to an accelerated and severe wasting
disease accompanied by higher expression of genes encoding
TH1-type of cytokines. IL-17A can also modulate the TH1
polarization in vitro in inhibitory sense, suppressing the
induction of the transcriptional factor T-bet, the “master
regulator” of TH1d i ﬀerentiation of T-cells. This datum
indicates that the presence of IL-17 within its receptor (IL-
17R)isafavorableprognosticfactorinthemodulationofthe
pathogenesis of IBD, diminishing the activation of T-cells in
TH1 sense.
These cytokines are produced by subsets of CD4+ T-
helper (Th) cells: in contrast to UC that is considered more
of a TH2 response and CD that is associated with TH1a n d
TH17 proﬁle [98–100]. But new T-cell subclasses Tregs exist
independently of TH1a n dT H2 and play a central role in
modulating IBD. In fact, there are new evidences that defects
in Treg cell function may underlie IBD and discuss evidence
that altered T-cell dependent responses to bacterial proteins
m a yb ec e n t r a lt oi t sa e t i o l o g y[ 101]. In IBD there is a hyper-
reactive immune response in the gut wall directed against
the commensal intestinal bacterial ﬂora, and the CD4 T-cells
dominate the adaptive immune response [102].
13. Tregs inIBD
Treg cells expressing FoxP3 and/or IL-10 have a role in the
immune homeostasis of the gut [103].
It has been well demonstrated in experimental colitis
in mice that Tregs not only prevent colitis but also block
the progression and reverse the pathology, via IL-10 and
Transforming Growth Factor (TGF)-beta-dependent and -
independent mechanisms [103], and they suppress both T-
cell-dependent colitis and intestinal bacterial inﬂammation
[104]. Furthermore, helminthes have been demonstrated
to protect against colonic inﬂammation, and Tregs were
suggested to be responsible for this protective eﬀect; inMediators of Inﬂammation 7
fact helminthes impede TH1a n dT H2 responses generating
an immunoregulatory environment via Treg, IL-10, and/or
TGF-beta [105].
In humans, during active IBD, there is an inverse
correlation between the frequency of peripheral Tregs and
the severity of disease [106, 107], and there is an increased
number of Tregs in the lamina propria, in mesenteric
lymph nodes, and inﬂamed intestinal mucosa, compared to
healthy controls [107, 108]. In addition, the frequency of
Tregs decreases with treatment and correlates with clinical
response [109]. It is possible that Tregs are recruited from
peripheral blood to the inﬂammation’s sites to regulate
immune homeostasis [110].
In vitro functional analyses of Tregs from the peripheral
blood or intestinal mucosa of IBD patients have shown
that Tregs have normal cell-contact-dependent, cytokine-
independent suppressive capacity, even against pathogenic
T-eﬀector cells derived from the inﬂamed mucosa [101]. In
addition, Tregs derived from IBD inﬂamed mucosa suppress
proliferation and cytokine production [111].
But, there are some diﬃculties to study mucosal Tregs
because the markers used for Tregs from peripheral blood
are not unique to Tregs from the lamina propria. Further-
more, nonsuppressive activated T eﬀectors, increased in IBD
mucosa, can express FoxP3 [112, 113]. Furthermore, func-
tional in vitro assays are performed without the inﬂuence
of the inﬂamed tissue, where diverse response to cytokines
or costimulatory interactions may modify Tregs suppressive
activity.Forexample,IL-23inhibitsthegenerationofcolonic
FoxP3+ Tregs [114–116].
In recent years, much interest has been attracted by
TLR that are essential in the development of antimicrobial
responses, by inducing the production of antimicrobial
proteins and peptides by a number of cells in the gut
epithelium. Activation of macrophages through TLR results
in the secretion of inﬂammatory cytokines and chemokines,
thus leading to development of inﬂammatory responses.
In addition, decreased IL-10 production in T-cells from
IBD patients or dendritic cells failure in inducing Tregs or
presence of T eﬀectors resistant to suppression can alter the
Tregs suppressive activity in vitro [117].
Current IBD therapies have a role on the number and
functions of Tregs. In children aﬀected by CD, there is an
increased number of colonic FoxP3+ cells after inﬂiximab
therapy [118]. In children, in fact, in contrast to adults, there
are reduced numbers of colonic Tregs compared to healthy
subjects.
Probiotics stimulate the generation of Tregs that produce
high levels of IL-10 and suppress the proliferation of eﬀector
T-cells in an IL-10-dependent manner [119].
Finally, recent evidence implicates TH17 cells in the
pathogenesis of Crohn’s disease [91].
14. TH17 inIBD
TH17 cells have been shown to play a role in the pathogenesis
of autoimmune and inﬂammatory diseases, including IBD.
Although Treg cells are eﬀectively recruited at inﬂamed
mucosa in IBD, it is possible that Treg cells may have
proinﬂammatory eﬀects through their ability to diﬀerentiate
into TH17 in the presence of IL-6 and/or IL-23 at sites of
inﬂammation [120].
TH17 associated cytokines (IL-17A, IL-17F, IL-21, IL-22)
are elevated in bioptic specimens from IBD inﬂamed colon
and in the sera during active disease. While IL-17 expression
is not detectable in normal colon, it is readily detectable in
CD colonic specimens, is related to disease severity, and is
signiﬁcantly lower in UC than in CD [121].
The role of IL-17A in colitis is controversial: it has
been shown to be proinﬂammatory (due to the produc-
tion of proinﬂammatory cytokines, as IL-6 and IL-8, and
chemokines, as MCP-1).
IL-21, with TGF-beta, drives TH17 diﬀerentiation, con-
tributing to the development of colitis. IL-22, derived
from inﬁltrating T-cells and NK, is protective and induces
antiapoptotic signaling pathways in the intestinal epithelial
cells maintaining the integrity of the epithelial barrier [121].
Genome-wide association studies have linked CD to a
number of IL-23 pathway genes, including the encoding
gene for IL-23 Receptor. Similar associations in IL-23
pathway genes have been observed in UC. IL-23R is a
key diﬀerentiation feature of CD4-TH17 eﬀector cells that
are critical in mediating antimicrobial defenses, is highly
expressed by TH17 cells, and has a role in their maintenance.
Several polymorphisms in the IL-23R gene locus were
associated with either susceptibility or resistance to CD
[122].
IL-23 is essential in mice for development of IBD and
has the major proinﬂammatory role. In absence of IL-23,
colonic levels of proinﬂammatory cytokines, as TNF-alpha,
IFN-gamma, and IL-6, are reduced, while Tregs colonic
population is greater.
IL-23 plays an essential role in the induction of intestinal
inﬂammation by innate immune mechanism. Its expression
is highly increased in the inﬂamed intestine but not in
systemic sites as those of the spleen and the liver [122].
The diﬀerentiation of inﬂammatory TH17 and sup-
pressive Treg subsets is reciprocally regulated by relative
concentrations of TGF-beta, with the concomitant presence
of proinﬂammatory cytokines favoring TH17 diﬀerentiation,
such as IL-6, or Tregs diﬀerentiation, such as retinoic acid.
The expansion and survival of TH17 T-cells are subsequently
mediated by IL-23 [121].
The homeostatic cytokine IL-7 is essential to the main-
tenance of colitogenic memory CD4 cells, critical to the
maintenance of experimental colitis.
In summary, the IL-23/IL-17 axis is linked to chronic
intestinal inﬂammation and has a beneﬁcial role in intestinal
protection and homeostasis.
15. Conclusions
Tregs and TH17 cells are two important T-cell function-
ally subpopulations characterized by a speciﬁc pattern of
cytokine production whose diﬀerentiation is modulated by
the cytokine microenvironment that has been demonstrated
to take part in the pathogenesis of autoimmune disease,
cancer, and organs allograft.8 Mediators of Inﬂammation
So, if in tumor the increase of Tregs and TH17 cells is
inversely correlated with a favorable prognosis, in the IBD
and celiac disease there are diﬀerent situations: while the
increase of Tregs prevents the autoimmunity reaction, an
amount due of TH17 cells promotes the outbreak of chronic
inﬂammation. Finally an increase on the proportion of
Tregs in the liver transplant correlates with a most favorable
success of the transplant, preventing reject and also allowing
to reduce the use of immune suppressives, reducing its
numerous side eﬀects. Further studies on the role of TH17
cells in allografts might be performed to make clear the
eﬀective negative role of these cells in the organs transplants.
In summary, Tregs and TH17 cells seem to represent use-
ful and eﬀective mediators in inﬂammation, autoimmunity,
cancer, and allograft rejection, and their serum and tissue
levels can be used in diagnosis, prognosis, and monitoring
of several diseases.
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